青少年和青年慢性淋巴细胞白血病患者的临床与分子特征及治疗模式
治疗前β2微球蛋白升高、Rai分期晚期、FISH检测del(11q)或del(17p)、IGHV未突变及CD38阳性与更短TTFT和OS相关。在曾接受口服靶向治疗的患者中,del(11q)或del(17p)及复杂核型与更短OS相关。
要点
- 治疗前β2微球蛋白升高、Rai晚期、del(11q)/del(17p)、IGHV未突变及CD38阳性提示预后更差。
- 接受口服靶向治疗者中,del(11q)/del(17p)和复杂核型与更短OS相关。
核心结论
- AYA CLL患者具有独特的临床和分子特征,部分高危因素与不良预后相关。
研究设计与样本
- 回顾性分析近二十年在本机构诊断的227例AYA CLL患者(年龄15-39岁)。
主要发现
- 治疗前β2微球蛋白升高、Rai分期晚期、del(11q)或del(17p)、IGHV未突变及CD38阳性与更短TTFT和OS相关。
- 在曾接受口服靶向治疗的患者中,del(11q)或del(17p)及复杂核型与更短OS相关。
- 携带del(11q)或del(17p)的患者至Richter转化时间更短,且更可能接受异基因造血干细胞移植。
临床怎么用
- 对AYA CLL患者应评估β2微球蛋白、Rai分期、FISH检测del(11q)/del(17p)、IGHV突变状态及CD38表达以进行风险分层。
- 接受口服靶向治疗的患者中,需关注del(11q)/del(17p)和复杂核型对生存的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukaemia (CLL) rarely presents in adolescent and young adult (AYA) patients (patients aged 15-39 years). Disease characteristics and outcomes of AYA patients with CLL are not well understood, particularly in the era of novel oral targeted therapies. We analysed outcomes of 227 AYA patients with CLL diagnosed in the last two decades and evaluated at our institution. Median time to first treatment (TTFT) was 2·2 years, and five- and 10-year overall survival (OS) were 90% and 78%, respectively. Pre-treatment elevated beta 2-microglobulin, advanced Rai stage, del(11q) or del(17p) by FISH, unmutated IGHV and CD38 positivity were associated with both shorter TTFT and OS. Within the subgroup of patients who received oral targeted therapy at any time, del(11q) or del(17p) and complex karyotype were associated with shorter OS. First-line treatment choice was significantly associated with time to second treatment (P < 0·001). Patients harbouring del(11q) or del(17p) experienced shorter time to Richter transformation and were more likely to undergo an allogeneic stem cell transplant. There was a significant association between age and both OS and time to Richter transformation. Our study is the first analysis of AYA patients with CLL with a large number of patients treated with oral targeted therapies.
引用
- Cherng HJ, Jammal N, Paul S, et al. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021. PMID: 33973230. doi:10.1111/bjh.17498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。